In PrEP: Long-acting antivirals for HIV prevention

Cell Host Microbe. 2022 Feb 9;30(2):148-150. doi: 10.1016/j.chom.2022.01.012.

Abstract

Two recent publications (Vidal et al., 2021; Xue et al., 2022) report highly potent inhibitors as candidates for HIV pre-exposure prophylaxis (PrEP). They provide strong evidence that administration of long-acting capsid or fusion inhibitors as PrEP offers robust protection against simian-human immunodeficiency virus in the rhesus macaque model of HIV infection.

Publication types

  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Animals
  • Anti-HIV Agents* / pharmacology
  • Anti-HIV Agents* / therapeutic use
  • HIV Infections* / drug therapy
  • HIV Infections* / prevention & control
  • Humans
  • Macaca mulatta
  • Simian Acquired Immunodeficiency Syndrome* / virology
  • Simian Immunodeficiency Virus*

Substances

  • Anti-HIV Agents